Normas internacionales

Immunotherapy holds the greatest promise for new and effective therapies in the post- antibiotic and personalized medicine eras. Proper balancing of pro- and anti-inflammatory signals will require fine-tuning to ensure the scale does not tip too far in either direction. It is also important to remember that these disease processes cannot be studied in isolation, as pathways important for the pathogenesis of one disease can be promoted for the treatment of another. Targeted therapy to modify both activating and suppressive pathways will be necessary for the control of immune responses desired for proper immunotherapy. These processes are two sides of the same coin, and our ability to tip the balance in whichever direction we choose will dictate the effectiveness of new treatments. While no single pathway is likely to hold the solution for any disease, multimodality therapy that targets both sides of the scale promises new therapies for the future.

REFERENCES

1. Brunstein, C.G., et al., Infusion of ex vivo expanded T regulatory cells in adults

transplanted with umbilical cord blood: safety profile and detection kinetics. Blood, 2011. 117(3): p. 1061-70.

2. Di Ianni, M., et al., Tregs prevent GVHD and promote immune reconstitution in HLA- haploidentical transplantation. Blood, 2011. 117: p. 3921-3928.

3. Lepelletier, Y., et al., Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol, 2006. 36(7): p. 1782-93.

4. Friedl, P., A.T. den Boer, and M. Gunzer, Tuning immune responses: diversity and adaptation of the immunological synapse. Nat Rev Immunol, 2005. 5(7): p. 532-45. 5. Oheim, M., et al., Principles of two-photon excitation fluorescence microscopy and other

nonlinear imaging approaches. Adv Drug Deliv Rev, 2006. 58(7): p. 788-808.

6. So, P.T.C., et al., Two-Photon Excitation Fluorescence Microscropy. Annu Rev Biomed Eng, 2000. 02: p. 399-429.

7. Friedman, R.S., J. Jacobelli, and M.F. Krummel, Mechanisms of T cell motility and arrest: deciphering the relationship between intra- and extracellular determinants. Semin Immunol, 2005. 17(6): p. 387-99.

8. Lee, S.H. and R. Dominguez, Regulation of actin cytoskeleton dynamics in cells. Mol Cells, 2010.

9. Machesky, L.M., et al., Mammalian actin-related protein 2/3 complex localizes to regions of lamellipodial protrusion and is composed of evolutionary conserved proteins. Biochem J, 1997. 328: p. 105-112.

10. Humphries, C.L., et al., Direct regulation of Arp2/3 complex activity and function by the actin binding protein coronin. J Cell Biol, 2002. 159(6): p. 993-1004.

11. Are, A.F., et al., The p65/RelA subunit of NF-kappaB interacts with actin-containing structures. Exp Cell Res, 2000. 256(2): p. 533-44.

12. Legrand-Poels, S., et al., Modulation of Nod2-dependent NF-kappaB signaling by the actin cytoskeleton. J Cell Sci, 2007. 120(Pt 7): p. 1299-310.

13. Nemeth, Z.H., et al., Disruption of the actin cytoskeleton results in nuclear factor-kappaB activation and inflammatory mediator production in cultured human intestinal epithelial cells. J Cell Physiol, 2004. 200(1): p. 71-81.

14. Kustermans, G., et al., Perturbation of actin dynamics induces NF-kB activation in

myelomonocytic cells through an NADPH oxidase-dependent pathway. Biochem J, 2005. 387: p. 531-540.

15. Oshima, K., et al., IKK epsilon regulates F actin assembly and interacts with Drosophila IAP1 in cellular morphogenesis. Curr Biol, 2006. 16(15): p. 1531-7.

16. Orlowski, R.Z. and A.S. Baldwin Jr, NF-kB as a therapeutic target in cancer. Trends Mol Med, 2002. 8(8): p. 385-389.

17. Vodanovic-Jankovic, S., et al., NF-kB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood, 2006. 107: p. 827-834. 18. Welch, M.D., A. Iwamatsu, and T.J. Mitchison, Actin polymerisation is induced by

Arp2/3 protein complex at the surface of Listeria monocytogenes. Nature, 1997. 385: p. 265-269.

19. Castro-Castro, A., et al., Coronin 1A promotes a cytoskeletal-based feedback loop that facilitates Rac1 translocation and activation. EMBO J, 2011. 30(19): p. 3913-27.

20. Jefferies, C.A. and L.A.J. O'Neill, Rac1 Regulates Interleukin 1-induced Nuclear Factor kappa B Activation in an Inhibitory Protein kappa Balpha -independent Manner by Enhancing the Ability of the p65 Subunit to Transactivate Gene Expression. Journal of Biological Chemistry, 2000. 275(5): p. 3114-3120.

21. Boimel, P.J., et al., Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res, 2012. 14(1): p. R23.

22. Wagner, P.L., et al., CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg, 2009. 137(3): p. 615-21. 23. Saigusa, S., et al., Stromal CXCR4 and CXCL12 expression is associated with distant

recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann Surg Oncol, 2010. 17(8): p. 2051-8.

24. Popple, A., et al., The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer, 2012. 106(7): p. 1306-13.

25. Clatot, F., et al., Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol, 2011. 47(11): p. 1062-8.

26. Hoellenriegel, J., et al., The Spiegelmer NOX-A12, a novel CXCL12 inhibtior, interferes with chronic lymhocytic leukemia cell motility and causes chemosensitization. Blood, 2014. 123: p. 1032-1039.

27. Hippen, K.L., et al., Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol, 2011. 23(6): p. 462-8.

28. Burgents, J.E., et al., The Immunosuppressive Tumor Microenvironment Is the Major Impediment to Successful Therapeutic Vaccination in Neu Transgenic Mice. J

Immunother, 2010. 33(482-391).

29. Lahl, K. and T. Sparwasser, In Vivo Depletion of Foxp3+ Treg Cells Using the DEREG Mouse Model, in Regulatory T Cells: Methods and Protocols, G. Kassiotis and A. Liston, Editors. 2011, Humana Press.

30. Curtin, J.F., et al., Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One, 2008. 3(4): p. e1983.

31. Chaudhary, B., et al., Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother, 2014. 63(2): p. 81-99.

32. Gottschalk, R.A., E. Corse, and J.P. Allison, Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol, 2012. 188(3): p. 976-80.

33. Hamid, O., et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 2013. 369(2): p. 134-44.

34. Topalian, S.L., et al., Safety, Activity, and Immune Correlates of Anti-PD1 Antibody in Cancer. New England Journal of Medicine, 2012. 366(26): p. 2443-2454.

35. Francisco, L.M., et al., PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med, 2009. 206(13): p. 3015-29.